Affiliation:
1. Post-graduate Student, Department of Chemistry and Pharmacognosy, Tyumen State Medical University (Tyumen, Russia) E-mail: igorpopow2013@yandex.ru
Abstract
Over th past decade, beta-blockers have shown their promise in the therapy of skin hemangiomas. Infantile hemangiomas are the most common soft tissue tumors occurring in 4-10% of children under the age of 1 year. Various methods are used to treat the disease: laser therapy, surgical exci-sion, cryodestruction, sclerosing, as well as conservative treatment with systemic glucocorticosteroids and beta-blockers administered enterally, topi-cally, and externally. Pharmacotherapy with the use of application dosage forms of beta-receptor antagonists is considered to be the most effective and safe method. This approach to treatment has several advantages over the oral method of administration: first, the convenience and painlessness of use, and secondly, the local effect on the pathological process, hence reducing the risk of systemic side effects (bradycardia, hypotension, bron-chospasm, insomnia). All these advantages emphasize the relevance of the development of soft dosage forms of beta-blockers. The patent RU 2471500 C2 “Use of beta-blocker for preparing drug for treating hemangiomas” proposes atenolol, betaxolol, bisoprolol, carvediol, metoprolol, nebivolol, propranolol and sotalol as antiangiogenic agents. The creation of soft dosage forms of beta-blockers with domestic transcutaneous enhancer Tizol gel is a solution to the problem of targeted delivery of active substances to the lesion site. For the development of new drugs, one of the most fundamen-tal areas of pharmaceutical science, pharmaceutical analysis, is of fundamental importance. The main objectives of pharmaceutical analysis are to determine the qualitative and quantitative characteristics of medicines. This article provides a review of the main methods for the analysis of beta-blockers used for the effective quality control of medicines, as well as methods for identifying, quantifying, and biopharmaceutically analyzing new ointments based on Tizol gel.
Publisher
Russian Vrach, Publishing House Ltd.
Reference40 articles.
1. Махотина М.В. Совершенствование технологии аптечного из-готовления мягких лекарственных форм на основе Тизоль® геля: дис. ... канд. фарм. наук: 14.04.01. Перм. гос. фармацевт. академия, Пермь. 2018. 197 с.
2. Инструкция по медицинскому применению лекарственного препарата Тизоль [Электронный ресурс]. URL: https://tisolium.ru/about-tisolium/instruktsiya/.
3. Поворознюк В.В., Орлик Т.В., Козицкая С.В. Новый препарат «ГИАЛГЕЛЬ» для лечения пациентов с остеоартрозом суста-вов II-III степени. Поликлиника. 2017; 2(2): 113–115.
4. Анисимова Т.Г. Теоретические аспекты создания и фармацев-тического анализа комбинаций мазей противогрибковых и про-тивовоспалительных препаратов с гелем «Тизоль». Вопросы биологической, медицинской и фармацевтической химии. 2021; 24(8): 49–55.
5. Кобелева Т.А., Сичко А.И., Илиев К.И. Анализ местных анесте-тиков и натрия диклофенака в мягких лекарственных формах на титансодержащей основе: Монография. Тамбов. 2017. 88 с.